SOURCE: Alzheimer's Drug Discovery Foundation

June 09, 2008 14:51 ET

Alzheimer's Drug Discovery Foundation Invites Scientists to Apply for Grant Award Program

NEW YORK, NY--(Marketwire - June 9, 2008) - The Alzheimer's Drug Discovery Foundation (ADDF) invites scientists from the biotechnology industry and academia to apply for a research grant through the Novel Approaches to Drug Discovery for Alzheimer's Disease award program. The goal of the program is to accelerate the discovery, development and clinical evaluation of effective therapies for Alzheimer's disease. This grant award is being made possible through a generous donation from Elan Corporation, plc (NYSE: ELN).

Only research programs with lead compounds are eligible. Target discovery and validation programs will not be accepted. Funds may be used for advancing the development of lead compounds through pre-clinical in-vitro and in-vivo evaluation including pharmacology, toxicology, pharmacokinetics, formulation chemistry and the conduct of pre-clinical proof-of-concept studies. A funding priority is Alzheimer's disease drug discovery in emerging biotechnology companies.

Applications are available at The application submission deadline date is October 1, 2008.

Applications will be reviewed by an independent Scientific Review Committee convened by ADDF and comprised of leading experts in the Alzheimer's drug discovery and development research field and biotechnology investment community. Selections will be made by December 31, 2008 and funding will be awarded in January 2009.

About the Alzheimer's Drug Discovery Foundation (ADDF)

The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity established in 2004 to expand upon the programs initiated by the Institute for the Study of Aging (ISOA), a private foundation founded by the Lauder family in 1998. Our mission is to accelerate drug discovery research for Alzheimer's disease through venture philanthropy. To date, ADDF and ISOA have awarded $33 million for over 240 research programs and conferences worldwide. For more information, visit the ADDF website at

About Elan

Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Our effort to develop treatment alternatives for patients and caregivers suffering from Alzheimer's disease includes research programs focused on modifying or halting the progression of the disease. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit

Contact Information